Compound 1 Amine Solvate Purification and Stable Polymorphs

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing processes for producing 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (Compound 1) generate impurities, requiring costly column chromatography for purification, and there is a need for a scalable, cost-effective process that meets regulatory purity requirements, as well as a stable polymorphic form of the drug.

Innovation Solution

A process involving the formation of amine solvates with certain organic amines to remove impurities, allowing for high-purity Compound 1 production without column chromatography, and the development of crystalline forms A and B polymorphs with specific X-ray diffraction patterns.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If column chromatography is used for purification, then purity requirement is met, but manufacturing cost and operational complexity increase

Engineering Contradiction:
ImprovepurityVSAvoidpurification process complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent changes the physical-chemical parameters of the compound by forming amine solvates, which alters the purification mechanism from chromatographic separation based on adsorption to crystallization-based separation based on solubility differences. This enables high-purity product obtention through simple filtration and washing operations, eliminating the need for complex column chromatography while maintaining regulatory purity requirements

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent introduces amine solvates as an intermediary form of the compound during the purification process. The amine solvate acts as a temporary intermediate that facilitates impurity removal through differential solubility and crystallization, allowing the main compound to be purified without direct use of complex chromatographic systems. After purification, the solvate can be removed to yield the final pure product

Inventive Principle:
Principle #24Intermediary (Mediator)

2Manufacturing precision

If column chromatography is used for purification, then purity requirement is met, but manufacturing cost increases

Engineering Contradiction:
ImprovepurityVSAvoidmanufacturing cost
Core Design Contradiction:
Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent employs inexpensive, readily available amine solvents that can be easily removed after serving their purification function. These solvates act as temporary, disposable intermediaries that enable low-cost purification through simple crystallization and filtration operations, replacing expensive column chromatography equipment and materials. The amine solvents are typically removed by evaporation or simple washing, leaving the purified product without requiring costly chromatographic media

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

By changing the compound into an amine solvate form, the patent exploits differences in solubility parameters between the solvate and impurities, enabling inexpensive filtration-based purification. This parameter change allows the use of simple, low-cost separation techniques rather than expensive chromatography, significantly reducing manufacturing costs while maintaining high purity levels required for pharmaceutical production

Inventive Principle:
Principle #35Parameter changes

3Productivity

If conventional synthesis process is used, then Compound 1 is produced, but impurities are generated requiring additional purification steps

Engineering Contradiction:
Improvesynthesis efficiencyVSAvoidimpurity generation
Core Design Contradiction:
ProductivityVSLoss of substance

Solution Approach 1:

The patent converts the harmful effect of impurity generation into a beneficial purification mechanism. By forming amine solvates, the patent creates a situation where impurities remain in the mother liquor while the main compound crystallizes out in pure form. The impurities that were previously problematic become the basis for separation, allowing the synthesis process to yield high-purity product directly without requiring extensive additional purification steps

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent performs preliminary action by forming the amine solvate during or immediately after the synthesis step, before final product isolation. This preliminary solvate formation prepares the mixture for efficient separation, allowing impurities to be removed in subsequent simple filtration or washing operations. The preliminary action of solvate formation enables the synthesis process to be more efficient overall by incorporating purification functionality into the synthesis workflow itself

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process achieves high-purity Compound 1 production efficiently and cost-effectively, providing stable polymorphic forms suitable for large-scale manufacturing and pharmaceutical applications.

Implementation Method 1

the discovery by Applicant that Compound 1 can form amine solvates with certain organic amines

Methodology Applied
Scientific EffectSolvation: Solvation

Implementation Method 2

Formation of such amine solvates by Compound 1 enables removal of certain impurities generated in the synthesis of Compound 1, to provide Compound 1 in high purity

Methodology Applied
Scientific EffectCrystallization: Crystallisation

Implementation Method 3

having an X-ray powder diffraction pattern comprising peaks at angular positions 15.8 and 18.6

Methodology Applied
Scientific EffectX-ray diffraction: X-Ray

Implementation Method 4

the angular positions may vary by ±0.2° 2θ as measured by X-ray powder diffraction

Methodology Applied
Scientific EffectDiffraction: Diffraction

Data Source

PatentUS20250361203A1Processes of making 3-fluoro-5-(((1s,2ar)-1,3,3,4,4 pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1h-cyclopenta[CD]inden-7-yl)oxy)benzonitrile and polymorphs thereof
Publication Date: 2025.11.27 NIKANG THERAPEUTICS INC
  • US20250361203A1 patent drawing
  • US20250361203A1 patent drawing
  • US20250361203A1 patent drawing

AI summary

The present disclosure provides certain processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro- 1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile (Compound 1) and certain polymorphs thereof. Also provided are pharmaceutical compositions comprising a crystalline polymorph form of Compound 1 and processes for preparing such polymorph forms.